Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vivos Therapeutics (VVOS) Non Operating Income (2022 - 2025)

Vivos Therapeutics' Non Operating Income history spans 4 years, with the latest figure at -$631000.0 for Q4 2025.

  • Quarterly results put Non Operating Income at -$631000.0 for Q4 2025, down 827.94% from a year ago — trailing twelve months through Dec 2025 was -$1.5 million (down 1255.05% YoY), and the annual figure for FY2025 was -$1.5 million, down 1246.36%.
  • Non Operating Income for Q4 2025 was -$631000.0 at Vivos Therapeutics, up from -$679000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $51000.0 in Q1 2023 to a low of -$679000.0 in Q3 2025.
  • The 4-year median for Non Operating Income is -$37500.0 (2022), against an average of -$123500.0.
  • The sharpest move saw Non Operating Income skyrocketed 234.21% in 2023, then crashed 3672.22% in 2025.
  • Year by year, Non Operating Income stood at -$38000.0 in 2022, then skyrocketed by 63.16% to -$14000.0 in 2023, then tumbled by 385.71% to -$68000.0 in 2024, then plummeted by 827.94% to -$631000.0 in 2025.
  • According to Business Quant data, Non Operating Income over the past three periods came in at -$631000.0, -$679000.0, and -$163000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.